Fortunately, many samples in our pan-cancer SNP array dataset were consistent with frequent SCNA both before and after genome doubling, enabling unambiguous inference for many samples without use of somatic point-mutation data. This aspect of cancer genome evolution was noted previously in breast cancer cytogenetic data 46. We note that manual review of ABSOLUTE results was performed prior to generation of the FACS validation data or analysis of the NCI60 cell-line ploidy estimates (Fig. 2a,b).
